Clene, Inc. (CLNN)
4.08
+0.06
(+1.49%)
USD |
NASDAQ |
Oct 02, 16:00
4.04
-0.04
(-0.98%)
After-Hours: 20:00
Clene Enterprise Value : 64.81M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 64.81M |
| October 01, 2026 | 64.04M |
| September 30, 2026 | 64.81M |
| September 29, 2026 | 65.06M |
| September 28, 2026 | 64.55M |
| September 25, 2026 | 67.62M |
| September 24, 2026 | 66.47M |
| September 23, 2026 | 67.49M |
| September 22, 2026 | 68.64M |
| September 21, 2026 | 70.69M |
| September 18, 2026 | 68.26M |
| September 17, 2026 | 65.70M |
| September 16, 2026 | 62.00M |
| September 15, 2026 | 64.04M |
| September 14, 2026 | 54.59M |
| September 11, 2026 | 58.29M |
| September 10, 2026 | 59.31M |
| September 09, 2026 | 60.21M |
| September 08, 2026 | 58.93M |
| September 04, 2026 | 61.87M |
| September 03, 2026 | 63.72M |
| September 02, 2026 | 65.83M |
| September 01, 2026 | 65.13M |
| August 31, 2026 | 67.36M |
| August 28, 2026 | 66.73M |
| Date | Value |
|---|---|
| August 27, 2026 | 69.79M |
| August 26, 2026 | 72.09M |
| August 25, 2026 | 69.41M |
| August 24, 2026 | 69.34M |
| August 21, 2026 | 67.88M |
| August 20, 2026 | 68.51M |
| August 19, 2026 | 66.21M |
| August 18, 2026 | 64.94M |
| August 17, 2026 | 66.34M |
| August 14, 2026 | 65.58M |
| August 13, 2026 | 66.21M |
| August 12, 2026 | 64.68M |
| August 11, 2026 | 68.51M |
| August 10, 2026 | 78.61M |
| August 07, 2026 | 80.14M |
| August 06, 2026 | 80.91M |
| August 05, 2026 | 81.42M |
| August 04, 2026 | 80.14M |
| August 03, 2026 | 78.99M |
| July 31, 2026 | 76.76M |
| July 30, 2026 | 77.08M |
| July 29, 2026 | 72.99M |
| July 28, 2026 | 76.44M |
| July 27, 2026 | 82.44M |
| July 24, 2026 | 81.55M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| NovelStem International Corp. | 2.190M |
| Brainstorm Cell Therapeutics, Inc. | 11.62M |
| Summit Therapeutics, Inc. | 12.62B |
| Kezar Life Sciences, Inc. | -11.12M |
| Protara Therapeutics, Inc. | 19.78M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -13.42M |
| Revenue (Quarterly) | 0.09M |
| Total Expenses (Quarterly) | 13.51M |
| EPS Diluted (Quarterly) | -1.084 |
| Gross Profit Margin (Quarterly) | -332.2% |
| Profit Margin (Quarterly) | -14.92K% |
| Earnings Yield | -86.09% |
| Normalized Earnings Yield | -62.12 |